BLFS (BioLife Solutions) Beta: 1.8561 (As of Jun. 27, 2026)


BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $28.64
GF Value $28.57
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Beta?

BioLife Solutions BLFS +4.25% 72 Beta is 1.8561 as of Jun. 27, 2026. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), BioLife Solutions's Beta is 1.8561.


BioLife Solutions  (NAS:BLFS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BioLife Solutions Beta Related Terms


BioLife Solutions Beta Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Beta Chart

BioLife Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 1.87 2.08 1.93 1.81

BioLife Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 1.42 1.56 1.81 1.77

BLFS vs KMTS, AZTA, ATRC: Beta Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Beta distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Beta falls into.


BLFS
72GF Score
BioLife Solutions Inc BLFS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLife Solutions Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.8561 mean?
BioLife Solutions (BLFS) has a Beta of 1.8561 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioLife Solutions and its competitors.
Is BioLife Solutions' Beta too high?
BioLife Solutions' current Beta is 1.8561. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Beta compare to KMTS and AZTA?
BioLife Solutions' Beta of 1.8561 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioLife Solutions and its competitors. BioLife Solutions's current Beta is 1.8561. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current Beta is 1.8561. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Beta is 1.8561 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

  • Beta: 1.8561
  • GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.64
Price
$28.57
GF Value